Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Fees A 3.00% closing fee and a 2.00% exit fee, each calculated on the total revolving commitments, along with a $375,000 arranger fee
Tirzepatide for Obesity Management We analyzed 12 randomized trials comparing two leading incretin-based therapies: Weight Reduction Retatrutide: 16.3 kg | 23.8% Tirzepatide: 11.8 kg | 16.8% Retatrutide demonstrated greater efficacy in both absolute and percentage weight loss
Tirzepatide demonstrated impressive results in SURMOUNT clinical trials, with participants achieving up to 22% body weight reduction over 68 weekssignificantly more than placebo or single-agent GLP-1 therapies
Glucagon-like peptide-1 receptor agonists (GLP-1RA) a class of drugs prescribed to treat type 2 diabetes and obesity have seen a surge of popularity in recent years
